Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
HBM Alpha Therapeutics is a biotechnology company focused on developing antibody therapeutics for rare genetic diseases, specifically congenital adrenal hyperplasia and polycystic ovary syndrome. The company’s innovative health technology platform aims to address these conditions while also having potential applications for other endocrinological diseases linked to hypothalamic-pituitary-adrenal axis dysregulation. By providing precision therapies, HBM Alpha Therapeutics seeks to enhance treatment options within the healthcare sector for patients suffering from these endocrine disorders.
Harbour Antibodies
Acquisition in 2016
Harbour Antibodies BV, established in 2006 and based in Rotterdam, Netherlands, specializes in the production of antibodies and VH domains for therapeutic applications. The company utilizes advanced transgenic mouse technology to engineer mice capable of generating high affinity human antibodies. It has developed two key types of human immunoglobulin gene transgenic mice: those that produce conventional tetrameric antibodies, known as H2L2 antibodies, which consist of two heavy and two light chains, and those that generate heavy chain-only antibodies (HCAbs), which lack light chains. The availability of HCAbs allows for the generation of soluble human VH domains, facilitating the creation of innovative multi-functional molecules. Harbour Antibodies' transgenic mouse lines are accessible to licensing partners, enhancing research and development in the field of antibody therapeutics. The company operates as a subsidiary of Harbour BioMed.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.